Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04866225 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04866225 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 6 participants.
The verdict
NCT04866225, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study is a Phase 1, open-label, non-randomized, 2-period, fixed-sequence, single-dose study of PF-06865571 in healthy male participants to characterize the ADME properties of \[14C\]PF-06865571 following oral administration; and to evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of PF-06865571 following oral administration of unlabeled PF-06865571 and IV administration of \[14C\]PF-06865571.
Interventions
- DRUG Oral [14C]PF-06865571
- DRUG Oral PF-06865571
- DRUG IV [14C]PF-06865571
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2021-05-11 |
| Est. Completion | 2021-08-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04866225
The ClinicalTrials.gov registry entry for NCT04866225 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Oral [14C]PF-06865571 is the first listed.
NCT04866225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04866225 about?
NCT04866225 is a clinical study titled "A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.". This study is a Phase 1, open-label, non-randomized, 2-period, fixed-sequence, single-dose study of PF-06865571 in healthy male participants to characterize the ADME properties of \[14C\]PF-06865571 following oral administration; and to evaluate the absolute oral bioavailability (F) and fraction abs...
What is the current status of trial NCT04866225?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2021-05-11. Estimated completion is 2021-08-06.
What interventions are being tested in trial NCT04866225?
The interventions under investigation include: Oral [14C]PF-06865571 (DRUG), Oral PF-06865571 (DRUG), IV [14C]PF-06865571 (DRUG).
Who is sponsoring clinical trial NCT04866225?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.